论文部分内容阅读
最近的廿年间研制新抗真菌剂的花费剧增,但甚至在生命垂危的情况下,可使用的新药却很少,而且在安全性,有效性及方便性等试验方面均未超过现有疗法。因为本模型是很接近人类疾病的。虽然新抗真菌剂的发展必须包括对动物体内的效力研究,但大多数的研究人员都首先进行体外实验。然而在体外实验中无法考虑毒性,以及对代谢物的感受性,或药物在宿主及病原体中的动力学反应和它们之间的相互关系。在动物体内进行的活力测定,可
The cost of developing new antifungals has skyrocketed in recent 20 years, but few new drugs are available even in dying conditions, and none of them exceeds existing treatments in terms of safety, efficacy and convenience . Because this model is very close to human disease. Although the development of new anti-fungal agents must include studies of efficacy in animals, most researchers first conduct in vitro experiments. However, toxicity can not be accounted for in vitro experiments, as does the sensitivity to metabolites, or the kinetic responses of drugs to hosts and pathogens, and their interrelationships. Determination of vitality in animals can be